fatostatin

Fatostatin is a **synthetic small molecule** (diarylthiazole derivative) that acts as an inhibitor of sterol regulatory element-binding proteins (**SREBPs**), key transcription factors that regulate genes involved in lipid and cholesterol biosynthesis. It was originally developed from a chemical library as an inhibitor of insulin-induced adipogenesis, and has since demonstrated the ability to suppress fatty acid, cholesterol, and triglyceride synthesis in cellular and animal models. Fatostatin displays anti-tumor activity in several cancer types, notably **prostate cancer and endometrial cancer**, by blocking SREBP maturation and nuclear translocation, leading to inhibition of cell proliferation, induction of cell cycle arrest (G2/M phase), and promotion of caspase-mediated apoptosis. There is growing evidence it can suppress tumor growth in vivo, and it may also inhibit androgen receptor signaling via SREBP blockade. Fatostatin additionally shows SREBP-independent effects, such as affecting mitotic spindle formation and potentially inducing ferroptosis via inhibition of the AKT/mTORC1 pathway[1][2][3][4][5][6].

Other names

fatostatin A